title: Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2.
abstract: Aromatic and heteroaromatic amines (ArNH(2)) represent a class of potential mutagens that after being metabolically activated covalently modify DNA. Activation of ArNH(2) in many cases starts with N-hydroxylation by P450 enzymes, primarily CYP1A2. Poor understanding of structure-mutagenicity relationships of ArNH(2) limits their use in drug discovery programs. Key factors that facilitate activation of ArNH(2) are revealed by exploring their reaction intermediates in CYP1A2 using DFT calculations. On the basis of these calculations and extensive analysis of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)Fe(III)-OO(-), in a three-step heterolytic mechanism. First, the distal oxygen of the oxidant abstracts proton from H-bonded ArNH(2). The subsequent proximal protonation of the resulting (CYP1A2)Fe(III)-OOH weakens both the O-O and the O-H bonds of the oxidant. Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH(-) via S(N)2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical. Thus, our proposed reaction offers a mechanistic explanation for previous observations that metabolism of aromatic amines could cause oxidative stress. The primary drivers for mutagenic potency of ArNH(2) are (i) binding affinity of ArNH(2) in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH(2), and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates. This leads to a strategy for designing mutagenicity free ArNH(2): Structural alterations in ArNH(2), which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.
authors: Department of Medicinal Chemistry, R&I iMed, AstraZeneca R&D, Pepparedsleden 1, S-431 83 Mölndal, Sweden. igor.shamovsky@astrazeneca.com
authors: Igor
authors: I
authors: Shamovsky
authors: Lena
authors: L
authors: Ripa
authors: Lena
authors: L
authors: Börjesson
authors: Christine
authors: C
authors: Mee
authors: Bo
authors: B
authors: Nordén
authors: Peter
authors: P
authors: Hansen
authors: Catrin
authors: C
authors: Hasselgren
authors: Mike
authors: M
authors: O'Donovan
authors: Peter
authors: P
authors: Sjö
mesh_terms: D000588:Amines / Q000737:chemistry* / Q000633:toxicity*; D019388:Cytochrome P-450 CYP1A2 / Q000378:metabolism*; D006801:Humans; D006841:Hydrocarbons, Aromatic / Q000737:chemistry* / Q000633:toxicity*; D008958:Models, Molecular; D009153:Mutagens / Q000737:chemistry* / Q000633:toxicity*
chemical_list: D000588:Amines; D006841:Hydrocarbons, Aromatic; D009153:Mutagens; D019388:Cytochrome P-450 CYP1A2